Triclabendazole Market Size, Share & Trends Report, 2022-2030
The global Triclabendazole market gathered revenue around USD 490 Million in 2021 and market is set to grow USD 632.9 Million by the end of 2030 and is estimated to expand at a modest CAGR of 4.1% during the prediction period 2022 to 2030.
Growth Factors:
Triclabendazole is a well-known anthelmintic flukicide that belongs to the benzimidazole chemical family. It is widely used on sheep, goats, and cattle, primarily as drenches and seldom in tablets, boluses, or other forms. Only triclabendazole is effective against the very early phases of liver fluke infection, from two weeks after infection to adulthood. Triclabendazole is one of the primary controlling measures for eradicating trematode Fasciola hepatica in livestock. Hence, the use of triclabendazole for animals is anticipated to increase during the forecast period, which is expected to boost the growth of the global market.
Report Scope of the Triclabendazole Market
|
Report Coverage |
Details |
|
Market Size |
US$ 632.9 Million by 2030 |
|
Growth Rate |
CAGR of 4.1% from 2022 to 2030 |
|
Largest Market |
North America |
|
Fastest Growing Market |
Asia Pacific |
|
Base Year |
2021 |
|
Forecast Period |
2022 to 2030 |
|
Segments Covered |
Dosage Form, Animal Type, Distribution Channel and Region, |
|
Companies Mentioned |
AdvaCare Pharma, RV Lifesciences Limited, Grampus Laboratories, Intas Pharmaceuticals Ltd., Shanghai Tongren Pharmaceutical Co., Ltd., Shijiazhuang Shimu Animal Pharmaceutical Co., Ltd, Siflon Drugs & Pharmaceuticals Pvt. Ltd., Elanco, Virbac, Bimeda, Inc., Chanelle Pharma, and Zoetis Health.. |
Increase in Incidence of Faciolas Hepatica (Liver Fluke)
Fasciola hepatica, also known as the common liver fluke, occurs in many areas of the world and is usually caused by F. hepatica. In general, fascioliasis is more common and widespread in animals than in people. In the U.K., fluke prevalence in adult dairy cattle has been reported to be 48% to 76%. Prevalence of F. hepatica has increased in the past few years, and fasciolosis has been reported in new areas, thought to be due to wetter summers and warmer winters.
Factors such as rise in demand for improved nutrition, particularly animal protein, and increase in focus on food safety are likely to boost the demand for triclabendazole medicine over the next few years. The demand for milk and milk products has increased in the past few years, which, in turn, is projected to fuel the growth of the global triclabendazole market during the forecast period. Hence, increase in incidence of Faciolas hepatica or liver fluke is anticipated to propel the global market.
Triclabendazole Market: Key Drivers
Rise in prevalence of liver fluke caused by trematode parasite is anticipated to drive the need of triclabendazole drugs for the treatment of the same
Fasciola hepatica, also known as the common liver fluke, occurs in many areas of the world and usually is caused by F. hepatica. In general, fascioliasis is more common and widespread in animals than in people.
Liver fluke affects sheep and cattle of all ages and can reduce live-weight gains by 10% in adults and 30% in lambs and calves. The weather has a significant effect on the prevalence of liver fluke, especially mild winters and wet summers. The first step toward more effective treatment and control on farms is to gain a better understanding of the infection cycle and seasonal hazards of liver fluke.
A range of products can be used to treat cattle and sheep for fluke. When choosing treatment plans, it is important to use drugs that target the stage most likely to be present within the animal at the time to help reduce selection pressure. Triclabendazole is the only product that is effective against the very early stages, from two weeks after infection to adults.
Market Segmentation: Triclabendazole Market
In terms of dosage form, the global triclabendazole market has been bifurcated into tablet and oral suspension
Based on animal type, the global triclabendazole market has been classified into cattle, sheep, goat, and others
Based on distribution channel, the global triclabendazole market has been divided into veterinary hospitals, veterinary clinics, pharmacies & drug stores, and others
Each of the segments has been analyzed in detail for market trends, recent trends, and developments, drivers, restraints, opportunities, and useful insights. The triclabendazole market report provides current and expected revenue (US$ Mn) for each of these segments from 2021 to 2031, considering 2020 as the base year. The compound annual growth rate (percentage CAGR) has been provided for each segment and market from 2021 to 2031 along with market size estimations.
North America to Lead Global Triclabendazole Market
In terms of region, the global triclabendazole market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global triclabendazole market in 2020, accounting for 30.9% share, owing to large livestock population, increase in spending on preventive health care, and rise in number of veterinary clinics in the U.S.
Europe held significant share of the global market in 2020, due to presence of several key players in animal health. It is likely to be an attractive market during the forecast period. This can be attributed to large livestock population and rise in prevalence of liver fluke in grazing animals.
Some of the prominent players in the Triclabendazole Market include:
Segments Covered in the Report
This research report offers market revenue, sales volume, production assessment and prognoses by classifying it on the basis of various aspects. Further, this research study investigates market size, production, consumption and its development trends at global, regional, and country level for the period of 2017 to 2030 and covers subsequent region in its scope:
Global Triclabendazole Market: Segmentation
By Geography
North America
Europe
Asia Pacific
Latin America
Middle East & Africa (MEA)
Key Points Covered in Triclabendazole Market Study:
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Triclabendazole Market
4. Market Overview
4.1. Introduction
4.1.1. Market Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Triclabendazole Market Analysis and Forecast, 2017–2030
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Prevalence rate of Fasciola hepatica in animal health
5.2. Sales Volume of Triclabendazole (Best effort Basis)
5.3. Pricing Analysis
5.4. Regulatory Scenario by Region/globally
5.5. COVID-19 Impact Analysis
6. Global Triclabendazole Market Analysis and Forecast, by Dosage Form
6.1. Introduction & Definition
6.1.1. Key Findings / Developments
6.2. Global Triclabendazole Market Value Forecast, by Dosage Form, 2017–2030
6.2.1. Tablet
6.2.2. Oral Suspension
6.3. Global Triclabendazole Market Attractiveness, by Dosage Form
7. Global Triclabendazole Market Analysis and Forecast, by Animal Type
7.1. Introduction & Definition
7.1.1. Key Findings / Developments
7.2. Global Triclabendazole Market Value Forecast, by Animal Type, 2017–2030
7.2.1. Cattle
7.2.2. Sheep
7.2.3. Goat
7.2.4. Others
7.3. Global Triclabendazole Market Attractiveness, by Animal Type
8. Global Triclabendazole Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.1.1. Key Findings / Developments
8.2. Global Triclabendazole Market Value Forecast, by Distribution Channel, 2017–2030
8.2.1. Veterinary Hospitals
8.2.2. Veterinary Clinics
8.2.3. Pharmacies & Drug Stores
8.2.4. Others
8.3. Global Triclabendazole Market Attractiveness, by Distribution Channel
9. Global Triclabendazole Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Global Triclabendazole Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. North America Triclabendazole Market Attractiveness, by Region
10. North America Triclabendazole Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. North America Triclabendazole Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2030
10.2.1. Tablet
10.2.2. Oral Suspension
10.3. North America Triclabendazole Market Value (US$ Mn) Forecast, by Animal Type, 2017–2030
10.3.1. Cattle
10.3.2. Sheep
10.3.3. Goat
10.3.4. Others
10.4. North America Triclabendazole Market Value Forecast, by Distribution Channel, 2017–2030
10.4.1. Veterinary Hospitals
10.4.2. Veterinary Clinics
10.4.3. Pharmacies & Drug Stores
10.4.4. Others
10.4.5. North America Triclabendazole Market Attractiveness, by Distribution Channel
10.5. North America Triclabendazole Market Value (US$ Mn) Forecast, by Country, 2017–2030
10.5.1. U.S.
10.5.2. Canada
10.6. North America Triclabendazole Market Attractiveness Analysis
10.6.1. By Dosage Form
10.6.2. By Animal Type
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Triclabendazole Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Europe Triclabendazole Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2030
11.2.1. Tablet
11.2.2. Oral Suspension
11.3. Europe Triclabendazole Market Value (US$ Mn) Forecast, by Animal Type, 2017–2030
11.3.1. Cattle
11.3.2. Sheep
11.3.3. Goat
11.3.4. Others
11.4. Europe Triclabendazole Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2030
11.4.1. Germany
11.4.2. U.K.
11.4.3. France
11.4.4. Spain
11.4.5. Italy
11.4.6. Rest of Europe
11.5. Europe Triclabendazole Market Attractiveness Analysis
11.5.1. By Dosage Form
11.5.2. By Animal Type
11.5.3. By Distribution Channel
11.5.4. By Country/Sub-region
12. Asia Pacific Triclabendazole Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Asia Pacific Triclabendazole Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2030
12.2.1. Tablet
12.2.2. Oral Suspension
12.3. Asia Pacific Triclabendazole Market Value (US$ Mn) Forecast, by Animal Type, 2017–2030
12.3.1. Cattle
12.3.2. Sheep
12.3.3. Goat
12.3.4. Others
12.4. Asia Pacific Triclabendazole Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2030
12.4.1. China
12.4.2. Japan
12.4.3. India
12.4.4. Australia & New Zealand
12.4.5. Rest of Asia Pacific
12.5. Asia Pacific Triclabendazole Market Attractiveness Analysis
12.5.1. By Dosage Form
12.5.2. By Animal Type
12.5.3. By Distribution Channel
12.5.4. By Country/Sub-region
13. Latin America Triclabendazole Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Latin America Triclabendazole Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2030
13.2.1. Tablet
13.2.2. Oral Suspension
13.3. Latin America Triclabendazole Market Value (US$ Mn) Forecast, by Animal Type, 2017–2030
13.3.1. Cattle
13.3.2. Sheep
13.3.3. Goat
13.3.4. Others
13.4. Latin America Triclabendazole Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2030
13.4.1. Brazil
13.4.2. Mexico
13.4.3. Rest of Latin America Latin America
13.5. Latin America Triclabendazole Market Attractiveness Analysis
13.5.1. By Dosage Form
13.5.2. By Animal Type
13.5.3. By Distribution Channel
13.5.4. By Country/Sub-region
14. Middle East & Africa Triclabendazole Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Middle East & Africa Triclabendazole Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2030
14.2.1. Tablet
14.2.2. Oral Suspension
14.3. Middle East & Africa Triclabendazole Market Value (US$ Mn) Forecast, by Animal Type, 2017–2030
14.3.1. Cattle
14.3.2. Sheep
14.3.3. Goat
14.3.4. Others
14.4. Middle East & Africa Triclabendazole Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2030
14.4.1. GCC Countries
14.4.2. South Africa
14.4.3. Rest of Middle East & Africa
14.5. Middle East & Africa Triclabendazole Market Attractiveness Analysis
14.5.1. By Dosage Form
14.5.2. By Animal Type
14.5.3. By Distribution Channel
14.5.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competition Matrix (by Tier and Size of companies)
15.2. Market Share / Position Analysis, by Company, 2020
15.3. Competitive Business Strategies
15.4. Company Profiles
15.4.1. AdvaCare Pharma
15.4.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.4.1.2. Financial Analysis
15.4.1.3. Growth Strategies
15.4.1.4. SWOT Analysis
15.4.2. RV Lifesciences Limited
15.4.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.4.2.2. Financial Analysis
15.4.2.3. Growth Strategies
15.4.2.4. SWOT Analysis
15.4.3. Grampus Laboratories
15.4.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.4.3.2. Financial Analysis
15.4.3.3. Growth Strategies
15.4.3.4. SWOT Analysis
15.4.4. Intas Pharmaceuticals Ltd
15.4.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.4.4.2. Financial Analysis
15.4.4.3. Growth Strategies
15.4.4.4. SWOT Analysis
15.4.5. Shanghai Tongren Pharmaceutical Co., Ltd.
15.4.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.4.5.2. Financial Analysis
15.4.5.3. Growth Strategies
15.4.5.4. SWOT Analysis
15.4.6. Shijiazhuang Shimu Animal Pharmaceutical Co., Ltd.
15.4.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.4.6.2. Financial Analysis
15.4.6.3. Growth Strategies
15.4.6.4. SWOT Analysis
15.4.7. Siflon Drugs & Pharmaceuticals Pvt. Ltd.
15.4.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.4.7.2. Financial Analysis
15.4.7.3. Growth Strategies
15.4.7.4. SWOT Analysis
15.4.8. Elanco
15.4.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.4.8.2. Financial Analysis
15.4.8.3. Growth Strategies
15.4.8.4. SWOT Analysis
15.4.9. Virbac
15.4.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.4.9.2. Financial Analysis
15.4.9.3. Growth Strategies
15.4.9.4. SWOT Analysis
15.4.10. Bimeda, Inc.
15.4.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.4.10.2. Financial Analysis
15.4.10.3. Growth Strategies
15.4.10.4. SWOT Analysis
15.4.11. Chanelle Pharma
15.4.11.1. Company Overview (HQ, Business Segments, Employee Strength)
15.4.11.2. Financial Analysis
15.4.11.3. Growth Strategies
15.4.11.4. SWOT Analysis
15.4.12. Zoetis Health
15.4.12.1. Company Overview (HQ, Business Segments, Employee Strength)
15.4.12.2. Financial Analysis
15.4.12.3. Growth Strategies
15.4.12.4. SWOT Analysis
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers